الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 168 |  |  |
| | | from | 168 | | |
Abstract
Liver cirrhosis is considered the end stage of a variety of chronic liver diseases, and is irreversible in its advanced stages. The major complication of liver cirrhosis is HCC. HCC represents an increased cause of mortality, which most patients miss the best opportunity for treatment because of the lacks of symptoms in the early stages.
AFP is considered the conventional tumor marker in cases of HCC but its level may increase in patients with other diseases such as LC. Also, AFP may not be elevated enough in HCC patients in early stages. Accordingly, finding another reliable tumor marker for HCC is required.
sHLA-G expression in human tumor tissues and may participate in tumor development so sHLA-G might serve as a novel clinical marker in the diagnosis of HCC. Therefore, in this study we investigated the role of sHLA-G in HCC patients. Also, we compared between sHLA-G and AFP in both HCC and LC patients.
The aim of this study is to:1-Asses the serum levels of soluble HLA-G ( sHLA-G) in patients with HCC . 2- Study the role of sHLA-G as a novel diagnostic marker of HCC by detecting its level in comparison with the conventional AFP.
The study was carried out in the Clinical Pathology Department, Faculty of Medicine, El-Minia University Hospital. It was conducted through the period from September, 2012 to April, 2013. The study included 25 apparently healthy volunteers who served as a control group, 25 patients with HCC and 25 patients with liver cirrhosis. Hence the study subjects were divided into the following groups:
Group I: It comprised 25 apparently healthy volunteers who served as control subjects.
Group II: It included 25 HCC on top of liver cirrhosis.
Group III: It consisted of 25 cirrhotic patients.
All individuals in the study were subjected to the following:
A-Clinical examination
B-Imaging (Abdominal ultrasound and Multi detector C.T. scan)
C-Laboratory Investigations.